“The results of our retrospective study support taking advantage of the Cxbladder test to identify patients who should be further evaluated for cancer and to spare those who likely do not have cancer from an unnecessary workup," says Badrinath Konety, MD, MBA.

Bladder cancer biomarker test accurately adjudicates atypical cytology

“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” according to Richard Pazdur, MD.

Bladder Ca: Genetic testing, targeted therapies signal a new era of precision medicine

"A more standardized protocol that is office based, reliable, and reproducible as well as cost- and time-efficient is required to entice more urologists to abandon the TRUS-BX approach," writes J. Brantley Thrasher, MD.

TP-Bx: The answer to rising infectious complications?

Reduced infection rate may drive increased use of the transperineal approach.

The case for transperineal prostate biopsy vs. the transrectal approach

"Ignoring the entire Quality category may be a risky strategy in 2020 and beyond," warns Robert A. Dowling, MD.

Can you afford to avoid MIPS participation?

"Category III codes are designated as temporary codes by the AMA. Even though the codes are considered temporary, they are an integral and important part of the system," write Jonathan Rubenstein, MD, and Mark Painter.

What are Category III codes, and how are they best used for billing?

"Irrespective of treatment, fewer than half of men reported the ability to maintain erections sufficient for intercourse at 5 years," writes Badar M. Mian, MD.

Study compares prostate cancer treatment functional outcomes

A radiolabeled small molecule that binds to prostate-specific membrane antigen is continuing to show promise for treating progressive metastatic castrate-resistant prostate cancer, according to researchers at the University of California, Los Angeles.

PSMA-targeted therapy well tolerated in men with mCRPC

Overcoming challenges of medical therapy starts with leveraging guidelines.

Stone management often falls short

Chronic opioid use is rare following radical prostatectomy in Europe. Slightly more than half of men undergoing RP in Sweden between 2007 and 2017 were found to have filled an opioid prescription, but the proportion who became chronic opioid users was less than 1%.

Risk of chronic opioid use low after RP

Results of a randomized controlled clinical trial provide a rationale for urologists to integrate behavioral treatments into their practice for managing men with lower urinary tract symptoms of overactive bladder, according to the study’s authors.

Trial supports combined behavioral, medical approach to treating OAB

“If the long-term results prove to be as positive as the short-term results, then this could provide an intermediate option for patients with recurrent bulbar urethral strictures," says Sean P. Elliott, MD, MS.

Drug-coated balloon found efficacious for strictures

Prostatic artery embolization offers a safe and durably effective treatment for urinary retention and gross hematuria in challenging non-index BPH patients, according to the results of a retrospective study published in Urology (Nov. 14, 2019 [Epub ahead of print]).

PAE safe, durable for retention, hematuria in non-index BPH patients

A new tool for kidney stone ablation demonstrates strong potential to dust and fragment stones more quickly and efficiently than devices currently available in the United States. However, clinical studies must be performed before this technology can be used during lithotripsy nationally.

Novel thulium laser fiber appears to outperform Holmium:YAG laser

Results of a cross-sectional study of adult American men show that adherence to a low-fat diet is associated with a lower serum testosterone level.

Low-fat diet linked with lower testosterone level

"Following an adverse liability verdict, this defendant urologist did not also want the jury deciding damages," writes Acacia Brush Perko, Esq.

Lack of emergent VCUG leads to costly settlement

"Contribution limits increased for 401(k)s, 403(b)s, and most 457 plans to $19,500, up from $19,000 in 2019," writes Jeff Witz, CFP.

Vol 48 No 2